Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma
暂无分享,去创建一个
[1] V. Thirumala,et al. Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistance. , 2020, Biochimica et biophysica acta. Molecular basis of disease.
[2] Chuong D. Hoang,et al. MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.
[3] D. Kuang,et al. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity , 2019, Cancer Immunology Research.
[4] P. Meldgaard,et al. EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non-small cell Lung Cancer Treated With Erlotinib. , 2019, Clinical lung cancer.
[5] A. Aref,et al. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance , 2019, Molecular Cancer.
[6] R. Weinberg,et al. Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells , 2019, Proceedings of the National Academy of Sciences.
[7] A. Addeo,et al. Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today? , 2019, Front. Oncol..
[8] Zhijian Zhang,et al. MicroRNA-382 inhibits cancer cell growth and metastasis in NSCLC via targeting LMO3 , 2019, Experimental and therapeutic medicine.
[9] A. Tsao,et al. Use of Immune Checkpoint Inhibitors in Mesothelioma , 2019, Current Treatment Options in Oncology.
[10] P. Black,et al. The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder Cancer. , 2019, Human gene therapy.
[11] C. Sears. DNA repair as an emerging target for COPD-lung cancer overlap. , 2019, Respiratory investigation.
[12] Zhongjun Liu,et al. Y‐box binding protein‐1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma , 2018, Cancer science.
[13] C. Huang,et al. LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway. , 2018, European review for medical and pharmacological sciences.
[14] R. Dighe,et al. The soluble ligand Y box-1 activates Notch3 receptor by binding to epidermal growth factor like repeats 20-23. , 2018, Archives of biochemistry and biophysics.
[15] Guiming Zhang,et al. Sex Differences in the Association between Night Shift Work and the Risk of Cancers: A Meta-Analysis of 57 Articles , 2018, Disease markers.
[16] Wenyuan Zhao,et al. The long noncoding RNA LINC00312 induces lung adenocarcinoma migration and vasculogenic mimicry through directly binding YBX1 , 2018, Molecular Cancer.
[17] Mi Young Lee,et al. The Potential Roles of Extracellular Vesicles in Cigarette Smoke-Associated Diseases , 2018, Oxidative medicine and cellular longevity.
[18] L. Philipsen,et al. Cold shock Y-box binding protein-1 acetylation status in monocytes is associated with systemic inflammation and vascular damage. , 2018, Atherosclerosis.
[19] S. Chiu,et al. Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: insights from in vitro and in vivo melanoma models , 2018, Scientific Reports.
[20] A. Pollice,et al. Oxidative Stress Causes Enhanced Secretion of YB-1 Protein that Restrains Proliferation of Receiving Cells , 2018, Genes.
[21] Yanqin Sun,et al. miR-216a-5p inhibits malignant progression in small cell lung cancer: involvement of the Bcl-2 family proteins , 2018, Cancer management and research.
[22] Toru Tanaka,et al. Mechanism responsible for inhibitory effect of indirubin 3′‐oxime on anticancer agent‐induced YB‐1 nuclear translocation in HepG2 human hepatocellular carcinoma cells , 2018, Experimental cell research.
[23] F. Hirsch,et al. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[24] Myung-Chul Kim,et al. Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma , 2018, BMC Cancer.
[25] D. Zips,et al. Stress-Induced Phosphorylation of Nuclear YB-1 Depends on Nuclear Trafficking of p90 Ribosomal S6 Kinase , 2018, International journal of molecular sciences.
[26] B. Yadav,et al. Expression and network analysis of YBX1 interactors for identification of new drug targets in lung adenocarcinoma , 2018, Journal of genomics.
[27] D. Beer,et al. Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer. , 2018, Cancer research.
[28] J. Testa,et al. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas , 2018, Journal of cellular physiology.
[29] M. Wiese,et al. Small‐molecule inhibitors of multidrug resistance‐associated protein 1 and related processes: A historic approach and recent advances , 2018, Medicinal research reviews.
[30] D. Baines,et al. Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung , 2018, Thorax.
[31] F. Meric-Bernstam,et al. Targeting the PI3K pathway in cancer: are we making headway? , 2018, Nature Reviews Clinical Oncology.
[32] N. Imamoto,et al. Y-box protein-associated acidic protein (YBAP1/C1QBP) affects the localization and cytoplasmic functions of YB-1 , 2018, Scientific Reports.
[33] T. Voet,et al. Identification of the tumour transition states occurring during EMT , 2018, Nature.
[34] Jia-bao Liu,et al. LncRNA DANCR Promotes Lung Cancer by Sequestering miR-216a , 2018, Cancer control : journal of the Moffitt Cancer Center.
[35] Jianbo Gao,et al. TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18a/PTEN axis , 2018, Cell & Bioscience.
[36] A. Shukla,et al. Exosomes from asbestos‐exposed cells modulate gene expression in mesothelial cells , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[37] M. Szołkowska,et al. Malignant pleural mesothelioma: main topics of American Society of Clinical Oncology clinical practice guidelines for diagnosis and treatment. , 2018, Journal of thoracic disease.
[38] R. Tsutsumi,et al. YBX1 at the crossroads of non-coding transcriptome, exosomal, and cytoplasmic granular signaling. , 2018, European journal of cell biology.
[39] Xiaoting Li,et al. LncRNA GAS5 regulates ischemic stroke as a competing endogenous RNA for miR-137 to regulate the Notch1 signaling pathway. , 2018, Biochemical and biophysical research communications.
[40] S. Gadgeel,et al. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer , 2018, Expert review of anticancer therapy.
[41] Monika Haemmerle,et al. From biomarkers to therapeutic targets—the promises and perils of long non-coding RNAs in cancer , 2017, Cancer and Metastasis Reviews.
[42] Han Liu,et al. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer. , 2017, Biochemical and biophysical research communications.
[43] Jifeng Feng,et al. High YBX1 expression indicates poor prognosis and promotes cell migration and invasion in nasopharyngeal carcinoma , 2017, Experimental cell research.
[44] C. Pirker,et al. Dysregulated Expression of the MicroRNA miR‐137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[45] Qingqing Zhu,et al. The biology, function and clinical implications of exosomes in lung cancer. , 2017, Cancer letters.
[46] W. Schiemann,et al. The WAVE3-YB1 interaction regulates cancer stem cells activity in breast cancer , 2017, Oncotarget.
[47] A. Berns,et al. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition , 2017, Clinical Cancer Research.
[48] Xuenong Zhang,et al. Multifunctional nanoparticles co‐delivering EZH2 siRNA and etoposide for synergistic therapy of orthotopic non‐small‐cell lung tumor , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[49] Fei Wang,et al. YB‐1 expression promotes pancreatic cancer metastasis that is inhibited by microRNA‐216a , 2017, Experimental cell research.
[50] R. Schekman,et al. Broad role for YBX1 in defining the small noncoding RNA composition of exosomes , 2017, Proceedings of the National Academy of Sciences.
[51] D. Bailey,et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. , 2017, The Lancet. Oncology.
[52] G. Matullo,et al. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. , 2017, Cancer letters.
[53] G. Zalcman,et al. A review of bevacizumab in the treatment of malignant pleural mesothelioma. , 2017, Future oncology.
[54] D. Sivakumar,et al. Identification of 2,4‐dihydroxy‐5‐pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein‐1 (YB‐1) and its therapeutic actions against breast cancer , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[55] A. Oronsky,et al. What's New in SCLC? A Review , 2017, Neoplasia.
[56] J. Hansen. Night Shift Work and Risk of Breast Cancer , 2017, Current Environmental Health Reports.
[57] J. Tamaru,et al. Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer. , 2017, International journal of oncology.
[58] Hongyun Li,et al. YBX1 promotes tumor growth by elevating glycolysis in human bladder cancer , 2017, Oncotarget.
[59] J. Aerts,et al. Novel insights into mesothelioma biology and implications for therapy , 2017, Nature Reviews Cancer.
[60] R. Visconti,et al. The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy , 2017, International journal of molecular sciences.
[61] Li Xu,et al. Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells , 2017, Cancer Chemotherapy and Pharmacology.
[62] Ruilian Li,et al. Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1 , 2017, Experimental and therapeutic medicine.
[63] F. Grossi,et al. Exosomes: a new horizon in lung cancer. , 2017, Drug discovery today.
[64] T. Guo,et al. Transcriptional activation of NANOG by YBX1 promotes lung cancer stem-like properties and metastasis. , 2017, Biochemical and biophysical research communications.
[65] Chengcheng Zhang,et al. miR-137 inhibits the proliferation of human non-small cell lung cancer cells by targeting SRC3. , 2017, Oncology letters.
[66] Y. Ung,et al. Postoperative Adjuvant Systemic Therapy in Completely Resected Non–Small‐Cell Lung Cancer: A Systematic Review , 2017, Clinical lung cancer.
[67] Nicolai J. Birkbak,et al. Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[68] M. Kris,et al. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] Ruowen Sun,et al. Silencing of Y-box binding protein-1 by RNA interference inhibits proliferation, invasion, and metastasis, and enhances sensitivity to cisplatin through NF-κB signaling pathway in human neuroblastoma SH-SY5Y cells , 2017, Molecular and Cellular Biochemistry.
[70] O. Lavrik,et al. At the Interface of Three Nucleic Acids: The Role of RNA-Binding Proteins and Poly(ADP-ribose) in DNA Repair , 2017, Acta naturae.
[71] A. Brenner,et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors , 2017, Investigational New Drugs.
[72] Å. Borg,et al. Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer , 2017, Oncotarget.
[73] B. Bay,et al. YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro , 2017, BMC Cancer.
[74] Jayantha Gunaratne,et al. YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro , 2017, BMC Cancer.
[75] J. Creaney,et al. A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ. , 2017, Cancer genomics & proteomics.
[76] Shuo Zhang,et al. miR-382 inhibits tumor progression by targeting SETD8 in non-small cell lung cancer. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[77] I. Vendrell,et al. Serum YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases , 2017, Journal of bone oncology.
[78] Walter J Curran,et al. Lung cancer: current therapies and new targeted treatments , 2017, The Lancet.
[79] Jie Huang,et al. Positive expression of Y-box binding protein 1 and prognosis in non-small cell lung cancer: a meta-analysis. , 2017, Oncotarget.
[80] Yunlong Liu,et al. Novel Serine 176 Phosphorylation of YBX1 Activates NF-κB in Colon Cancer* , 2017, The Journal of Biological Chemistry.
[81] Jing Liu,et al. Long noncoding RNA HULC modulates the phosphorylation of YB‐1 through serving as a scaffold of extracellular signal–regulated kinase and YB‐1 to enhance hepatocarcinogenesis , 2016, Hepatology.
[82] D. Vallone,et al. The tumor-associated YB-1 protein: new player in the circadian control of cell proliferation , 2016, Oncotarget.
[83] R. Ni,et al. Hyper-O-GlcNAcylation of YB-1 affects Ser102 phosphorylation and promotes cell proliferation in hepatocellular carcinoma. , 2016, Experimental cell research.
[84] J. Jia,et al. Antimicrobial peptide LL-37 promotes YB-1 expression, and the viability, migration and invasion of malignant melanoma cells , 2016, Molecular medicine reports.
[85] A. Miyajima,et al. Y-box binding protein-1 promotes hepatocellular carcinoma-initiating cell progression and tumorigenesis via Wnt/β-catenin pathway , 2016, Oncotarget.
[86] O. Lavrik,et al. Y-box-binding protein 1 as a non-canonical factor of base excision repair. , 2016, Biochimica et biophysica acta.
[87] A. Sorokin,et al. Transportin-1-dependent YB-1 nuclear import. , 2016, Biochemical and biophysical research communications.
[88] F. Setién,et al. Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer , 2016, Proceedings of the National Academy of Sciences.
[89] Toru Tanaka,et al. Four nucleocytoplasmic-shuttling proteins and p53 interact specifically with the YB-NLS and are involved in anticancer reagent-induced nuclear localization of YB-1. , 2016, Biochemical and biophysical research communications.
[90] T. Rauen,et al. Cold shock protein YB-1 is involved in hypoxia-dependent gene transcription. , 2016, Biochemical and biophysical research communications.
[91] R. Simpson,et al. Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo , 2016, Scientific Reports.
[92] T. Jacks,et al. Circadian Rhythm Disruption Promotes Lung Tumorigenesis. , 2016, Cell metabolism.
[93] Dandan Zong,et al. Notch signaling in lung diseases: focus on Notch1 and Notch3 , 2016, Therapeutic advances in respiratory disease.
[94] W. Guo,et al. YBX1 regulates tumor growth via CDC25a pathway in human lung adenocarcinoma , 2016, Oncotarget.
[95] Guang-Biao Zhou,et al. Long non-coding RNA stabilizes the Y-box-binding protein 1 and regulates the epidermal growth factor receptor to promote lung carcinogenesis , 2016, Oncotarget.
[96] A. Stewart,et al. Multiomic Analysis of the UV-Induced DNA Damage Response , 2016, Cell reports.
[97] A. Pollice,et al. ΔNp63α controls YB‐1 protein stability: evidence on YB‐1 as a new player in keratinocyte differentiation , 2016, Genes to cells : devoted to molecular & cellular mechanisms.
[98] N. Nasreen,et al. Nanoparticle-based targeted gene therapy for lung cancer. , 2016, American journal of cancer research.
[99] Kazuhisa Takahashi,et al. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells. , 2016, Biochemical and biophysical research communications.
[100] Zhendong Hu,et al. Y-box-binding protein 1 promotes tumor progression and inhibits cisplatin chemosensitivity in esophageal squamous cell carcinoma. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[101] K. O'Byrne,et al. Lung cancer stem cells: The root of resistance. , 2016, Cancer letters.
[102] Thomas D. Wu,et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.
[103] S. Finn,et al. Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. , 2016, Pharmacology & therapeutics.
[104] F. Mraiche,et al. p90 ribosomal S6 kinase: a potential therapeutic target in lung cancer , 2016, Journal of Translational Medicine.
[105] B. Wang,et al. Overexpression of YB1 C‐terminal domain inhibits proliferation, angiogenesis and tumorigenicity in a SK‐BR‐3 breast cancer xenograft mouse model , 2016, FEBS open bio.
[106] Abdel Kareem Azab,et al. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy , 2015, Hypoxia.
[107] S. Maddika,et al. HACE1 mediated K27 ubiquitin linkage leads to YB-1 protein secretion. , 2015, Cellular signalling.
[108] P. Curmi,et al. Poly(ADP-ribosyl)ation as a new posttranslational modification of YB-1. , 2015, Biochimie.
[109] Ahmedin Jemal,et al. Global trends of lung cancer mortality and smoking prevalence. , 2015, Translational lung cancer research.
[110] S. Toyokuni,et al. Malignant mesothelioma as an oxidative stress-induced cancer: An update. , 2015, Free radical biology & medicine.
[111] Shuzhi Zang,et al. MicroRNA-137 inhibits cell migration and invasion by targeting bone morphogenetic protein-7 (BMP7) in non-small cell lung cancer cells. , 2015, International journal of clinical and experimental pathology.
[112] Yunlong Liu,et al. Critical role of phosphorylation of serine 165 of YBX1 on the activation of NF-κB in colon cancer , 2015, Oncotarget.
[113] Lijie He,et al. Twist contributes to proliferation and epithelial-to-mesenchymal transition-induced fibrosis by regulating YB-1 in human peritoneal mesothelial cells. , 2015, The American journal of pathology.
[114] Meng Li,et al. Clinicopathological and prognostic significance of Twist overexpression in NSCLC , 2015, Oncotarget.
[115] Yong-mei Song,et al. A critical role for the long non‐coding RNA GAS5 in proliferation and apoptosis in non‐small‐cell lung cancer , 2015, Molecular carcinogenesis.
[116] E. Izaurralde,et al. Towards a molecular understanding of microRNA-mediated gene silencing , 2015, Nature Reviews Genetics.
[117] S. Catalani,et al. Reactive oxygen species a double-edged sword for mesothelioma , 2015, Oncotarget.
[118] P. Ott,et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. , 2015 .
[119] S. Dunn,et al. Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells , 2015, Oncotarget.
[120] J. Zhao,et al. lncRNA GAS5 enhances G1 cell cycle arrest via binding to YBX1 to regulate p21 expression in stomach cancer , 2015, Scientific Reports.
[121] P. Sorensen,et al. Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis. , 2015, Cancer cell.
[122] R. Simpson,et al. YBX1/YB-1 induces partial EMT and tumourigenicity through secretion of angiogenic factors into the extracellular microenvironment , 2015, Oncotarget.
[123] Zhongyi Cheng,et al. Suberoylanilide Hydroxamic Acid Treatment Reveals Crosstalks among Proteome, Ubiquitylome and Acetylome in Non-Small Cell Lung Cancer A549 Cell Line , 2015, Scientific Reports.
[124] P. Sorensen,et al. YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1 , 2015, The Journal of cell biology.
[125] S. Kulp,et al. A novel HIF-1α-integrin-linked kinase regulatory loop that facilitates hypoxia-induced HIF-1α expression and epithelial-mesenchymal transition in cancer cells , 2015, Oncotarget.
[126] Jun Cui,et al. YB-1 overexpression promotes a TGF-β1-induced epithelial-mesenchymal transition via Akt activation. , 2015, Biochemical and biophysical research communications.
[127] C. Rudin,et al. Small cell lung cancer: Where do we go from here? , 2015, Cancer.
[128] I. Petruseva,et al. Y-box binding protein 1 (YB-1) promotes detection of DNA bulky lesions by XPC-HR23B factor , 2015, Biochemistry (Moscow).
[129] H. Checkoway,et al. Night Shift Work and Lung Cancer Risk Among Female Textile Workers in Shanghai, China , 2015, Journal of occupational and environmental hygiene.
[130] Shiladitya Sengupta,et al. New paradigms in the repair of oxidative damage in human genome: mechanisms ensuring repair of mutagenic base lesions during replication and involvement of accessory proteins , 2015, Cellular and Molecular Life Sciences.
[131] B. Shapiro,et al. Triggering of RNA Interference with RNA–RNA, RNA–DNA, and DNA–RNA Nanoparticles , 2014, ACS nano.
[132] Chirayu Pankaj Goswami,et al. PROGgeneV2: enhancements on the existing database , 2014, BMC Cancer.
[133] Leonid Peshkin,et al. A Noncanonical Frizzled2 Pathway Regulates Epithelial-Mesenchymal Transition and Metastasis , 2014, Cell.
[134] K. Syrigos,et al. mTOR pathway: A current, up-to-date mini-review (Review) , 2014, Oncology letters.
[135] B. Ghanim,et al. Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. , 2014, American journal of respiratory and critical care medicine.
[136] A. Schrader,et al. Clinical significance of epithelial-mesenchymal transition , 2014, Clinical and Translational Medicine.
[137] David C. Rice,et al. Frequent Coamplification and Cooperation between C-MYC and PVT1 Oncogenes Promote Malignant Pleural Mesothelioma , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[138] T. Uchiumi,et al. Targeting ribosomal S6 kinases/Y‐box binding protein‐1 signaling improves cellular sensitivity to taxane in prostate cancer , 2014, The Prostate.
[139] M. Kitagawa,et al. YB‐1 promotes transcription of cyclin D1 in human non‐small‐cell lung cancers , 2014, Genes to cells : devoted to molecular & cellular mechanisms.
[140] R. Stahel,et al. GAS5 long non-coding RNA in malignant pleural mesothelioma , 2014, Molecular Cancer.
[141] R. Lai,et al. YB-1 regulates Sox2 to coordinately sustain stemness and tumorigenic properties in a phenotypically distinct subset of breast cancer cells , 2014, BMC Cancer.
[142] J. Fletcher,et al. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma , 2014, British Journal of Cancer.
[143] B. Han,et al. Association of XPC Polymorphisms and Lung Cancer Risk: A Meta-Analysis , 2014, PloS one.
[144] S. Chiu,et al. YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin , 2014, Oncotarget.
[145] K. Jung,et al. A molecular targeting against nuclear factor-κB, as a chemotherapeutic approach for human malignant mesothelioma , 2014, Cancer medicine.
[146] H. Moch,et al. PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[147] Peixuan Guo,et al. Stable RNA nanoparticles as potential new generation drugs for cancer therapy. , 2014, Advanced drug delivery reviews.
[148] G. Semenza. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. , 2014, Annual review of pathology.
[149] F. Tanaka,et al. Clinical Significance of Epithelial-Mesenchymal Transition-Associated Markers in Malignant Pleural Mesothelioma , 2014, Oncology.
[150] F. Tacke,et al. High prevalence of Y-box protein-1/p18 fragment in plasma of patients with malignancies of different origin , 2014, BMC Cancer.
[151] Jan Budczies,et al. Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer , 2013, PloS one.
[152] E. Hopper-Borge,et al. Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma , 2013, Journal of cancer research updates.
[153] V. Evdokimova,et al. The proteolytic YB-1 fragment interacts with DNA repair machinery and enhances survival during DNA damaging stress , 2013, Cell cycle.
[154] Jie Huang,et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. , 2013, Journal of the National Cancer Institute.
[155] U. Naumann,et al. YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells , 2013, Journal of Translational Medicine.
[156] S. Dooley,et al. Cold shock Y-box protein-1 proteolysis autoregulates its transcriptional activities , 2013, Cell Communication and Signaling.
[157] K. Darwiche,et al. Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a Phase II, randomized study , 2013, Drug design, development and therapy.
[158] T. Nakano,et al. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma , 2013, BMC Cancer.
[159] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[160] K. Kuroiwa,et al. YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α , 2013, Cancer Immunology, Immunotherapy.
[161] R. Rosell,et al. The role of SOX2 in small cell lung cancer, lung adenocarcinoma and squamous cell carcinoma of the lung. , 2013, Translational lung cancer research.
[162] A. Rosenwald,et al. The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival , 2013, Leukemia.
[163] L. Ovchinnikov,et al. YB-1 Synthesis Is Regulated by mTOR Signaling Pathway , 2012, PloS one.
[164] Ping Liu,et al. YB-1 immunization combined with regulatory T-cell depletion induces specific T-cell responses that protect against neuroblastoma in the early stage. , 2012, Acta biochimica et biophysica Sinica.
[165] B. Bao,et al. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. , 2012, Biochimica et biophysica acta.
[166] Robert Gentleman,et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.
[167] H. Izumi,et al. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer. , 2012, Clinical lung cancer.
[168] Sarah E Seton-Rogers,et al. Therapeutics: siRNAs jump the hurdle , 2012, Nature Reviews Cancer.
[169] T. Brabletz. To differentiate or not — routes towards metastasis , 2012, Nature Reviews Cancer.
[170] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[171] H. Mukhtar,et al. Dual inhibition of phosphatidylinositol 3‐kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin , 2012, International journal of cancer.
[172] A. Shelling,et al. YB-1, the E2F pathway, and regulation of tumor cell growth. , 2012, Journal of the National Cancer Institute.
[173] P. Lara,et al. MVP and vaults: a role in the radiation response , 2011, Radiation oncology.
[174] T. Uchiumi,et al. Twist1 and Y‐box‐binding protein‐1 promote malignant potential in bladder cancer cells , 2011, BJU international.
[175] P. Tan,et al. Prognostic Association of YB-1 Expression in Breast Cancers: A Matter of Antibody , 2011, PloS one.
[176] T. Cramer,et al. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[177] J. Blenis,et al. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.
[178] B. Ghanim,et al. Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo: Synergism with Chemotherapy , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[179] P. Boor,et al. Extracellular YB-1 Blockade in Experimental Nephritis Upregulates Notch-3 Receptor Expression and Signaling , 2011, Nephron Experimental Nephrology.
[180] S. Chiou,et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. , 2010, Cancer research.
[181] T. Betsuyaku,et al. Cigarette smoke induces nucleic-acid oxidation in lung fibroblasts. , 2010, American journal of respiratory cell and molecular biology.
[182] M. Gleave,et al. Molecular Decoy to the Y-Box Binding Protein-1 Suppresses the Growth of Breast and Prostate Cancer Cells whilst Sparing Normal Cell Viability , 2010, PloS one.
[183] Ken Yamamoto,et al. P300/CBP‐associated factor regulates Y‐box binding protein‐1 expression and promotes cancer cell growth, cancer invasion and drug resistance , 2010, Cancer science.
[184] H. Pass,et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation , 2010, Proceedings of the National Academy of Sciences.
[185] M. Bushell,et al. Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1 , 2010, Oncogene.
[186] C. Eaves,et al. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. , 2010, Cancer research.
[187] A. Braithwaite,et al. Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing , 2010, Oncogene.
[188] Ping Chen,et al. Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. , 2009, The International journal of biological markers.
[189] R. Orentas,et al. Discovery of YB-1 as a new immunological target in neuroblastoma by vaccination in the context of regulatory T cell blockade. , 2009, Acta biochimica et biophysica Sinica.
[190] Ping Chen,et al. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. , 2009, Clinical lung cancer.
[191] C. Tognon,et al. Reduced proliferation and enhanced migration: Two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1 , 2009, Cell cycle.
[192] T. Gu,et al. Phosphorylation of the SSBP2 and ABL proteins by the ZNF198‐FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide‐specific MS , 2009, Proteomics.
[193] S. Dooley,et al. YB-1 Acts as a Ligand for Notch-3 Receptors and Modulates Receptor Activation* , 2009, The Journal of Biological Chemistry.
[194] W. Lam,et al. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1 , 2009, Oncogene.
[195] S. Dooley,et al. Y-box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen , 2009, EMBO reports.
[196] T. Triche,et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. , 2009, Cancer cell.
[197] So Ri Kim,et al. Impact of oxidative stress on lung diseases , 2009, Respirology.
[198] J. Moolman-Smook,et al. RBBP6 interacts with multifunctional protein YB-1 through its RING finger domain, leading to ubiquitination and proteosomal degradation of YB-1. , 2008, Journal of molecular biology.
[199] Yong-Yeon Cho,et al. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells , 2008, Breast Cancer Research.
[200] K. Kohno,et al. Regulatory Role of Human AP-Endonuclease (APE1/Ref-1) in YB-1-Mediated Activation of the Multidrug Resistance Gene MDR1 , 2008, Molecular and Cellular Biology.
[201] T. Mak,et al. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a) , 2008, Proceedings of the National Academy of Sciences.
[202] F. Schmidt. Meta-Analysis , 2008 .
[203] T. Nielsen,et al. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy , 2007, Breast Cancer Research.
[204] M. Clarke,et al. Cancer stem cells and tumor metastasis: first steps into uncharted territory. , 2007, Cell stem cell.
[205] C. Heeschen,et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.
[206] C. Garbe,et al. The increased expression of Y box‐binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance , 2007, International journal of cancer.
[207] B. Gansbacher,et al. Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents. , 2006, Cancer research.
[208] Shuhua Ma,et al. Reduced Stability of Mitogen-activated Protein Kinase Kinase-2 mRNA and Phosphorylation of Poly(A)-binding Protein (PABP) in Cells Overexpressing PABP* , 2006, Journal of Biological Chemistry.
[209] G. Ceresoli,et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. , 2006, Lung cancer.
[210] V. Evdokimova,et al. Proteasome‐mediated cleavage of the Y‐box‐binding protein 1 is linked to DNA‐damage stress response , 2005, The EMBO journal.
[211] M. Ladanyi. Implications of P16/CDKN2A deletion in pleural mesotheliomas. , 2005, Lung cancer.
[212] E. Yorida,et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells , 2005, Oncogene.
[213] P. Schlag,et al. YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene , 2005, Oncogene.
[214] H. Clevers,et al. Wnt signalling in stem cells and cancer , 2005, Nature.
[215] L. Ovchinnikov,et al. YB-1 Autoregulates Translation of Its Own mRNA at or prior to the Step of 40S Ribosomal Subunit Joining , 2005, Molecular and Cellular Biology.
[216] D. Ma,et al. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines. , 2004, Oncology reports.
[217] G. Tortora,et al. The role of EGFR inhibitors in nonsmall cell lung cancer , 2004, Current opinion in oncology.
[218] M. Lebel,et al. YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. , 2004, Nucleic acids research.
[219] A. Tossavainen. Global Use of Asbestos and the Incidence of Mesothelioma , 2004, International journal of occupational and environmental health.
[220] C. Witt,et al. Nuclear YB‐1 expression as a negative prognostic marker in nonsmall cell lung cancer , 2004, European Respiratory Journal.
[221] Sunil Singhal,et al. Gene expression profiling of malignant mesothelioma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[222] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[223] L. Penalva,et al. Poly(A)-binding Protein Positively Affects YB-1 mRNA Translation through Specific Interaction with YB-1 mRNA* , 2003, The Journal of Biological Chemistry.
[224] Satoru Takahashi,et al. Regulation of YB-1 gene expression by GATA transcription factors. , 2003, Biochemical and biophysical research communications.
[225] K. Kohno,et al. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer , 2002, Journal of Cancer Research and Clinical Oncology.
[226] H. Uramoto,et al. p73 Interacts with c-Myc to Regulate Y-box-binding Protein-1 Expression* , 2002, The Journal of Biological Chemistry.
[227] M. Bittner,et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. , 2002, Cancer cell.
[228] Y. Maehara,et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[229] Y. Soini,et al. The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[230] P. Schlag,et al. Hyperthermia-induced Nuclear Translocation of Transcription Factor YB-1 Leads to Enhanced Expression of Multidrug Resistance-related ABC Transporters* , 2001, The Journal of Biological Chemistry.
[231] S. Khuder,et al. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. , 2001, Lung cancer.
[232] H. Takano,et al. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. , 1999, Cancer research.
[233] K. Kohno,et al. Direct Involvement of the Y-box Binding Protein YB-1 in Genotoxic Stress-induced Activation of the Human Multidrug Resistance 1 Gene* , 1998, The Journal of Biological Chemistry.
[234] K. Kohno,et al. Nuclear translocation of the Y‐box binding protein by ultraviolet irradiation , 1997, FEBS letters.
[235] K. Kohno,et al. Structural and functional analysis of the human Y-box binding protein (YB-1) gene promoter. , 1996, Nucleic acids research.
[236] K Botzenhart,et al. Reactive Oxygen Species , 2014 .
[237] I. Weinstein,et al. Amplification and expression of the human cyclin D gene in esophageal cancer. , 1992, Cancer research.
[238] A. Wolffe,et al. The Y-box factors: a family of nucleic acid binding proteins conserved from Escherichia coli to man. , 1992, The New biologist.
[239] H. Liu,et al. Treatment of small cell lung cancer. , 1991, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.
[240] D. K. Didier,et al. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[241] R. Stahel,et al. GAS 5 long non-coding RNA in malignant pleural mesothelioma , 2017 .
[242] C. L. Ventola. Cancer Immunotherapy, Part 3: Challenges and Future Trends. , 2017, P & T : a peer-reviewed journal for formulary management.
[243] Self-Concept Variables. Sex Differences in , 2016 .
[244] G. Giaccone,et al. Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. , 2016, Journal of oncology practice / American Society of Clinical Oncology.
[245] K. Kerr,et al. Survival from malignant mesothelioma: where are we now? , 2015, The journal of the Royal College of Physicians of Edinburgh.
[246] W. Bi,et al. miR-382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[247] B. Schittek,et al. Y-box binding protein 1--a prognostic marker and target in tumour therapy. , 2014, European journal of cell biology.
[248] L. Ovchinnikov,et al. YB‐1 protein: functions and regulation , 2014, Wiley interdisciplinary reviews. RNA.
[249] C. Print,et al. YB-1: oncoprotein, prognostic marker and therapeutic target? , 2013, The Biochemical journal.
[250] Yong Lin,et al. NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. , 2011, Frontiers in bioscience.
[251] J. Rich,et al. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. , 2010, Current topics in microbiology and immunology.
[252] H. Izumi,et al. Twist promotes tumor cell growth through YB-1 expression. , 2008, Cancer research.
[253] M. Volm,et al. Prognostic relevance of c-Myc and caspase-3 for patients with non-small cell lung cancer. , 2000, Oncology reports.
[254] T. Chao,et al. Combination chemoimmunotherapy with interferon-alpha and cisplatin in patients with advanced non-small cell lung cancer. , 1995, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed.
[255] A. Rusanov. [Stomach cancer]. , 1974, Voprosy onkologii.
[256] A Critical , 2022 .